• Detects SNVs, Indels, CNVs, and rearrangements
• Designed to predict responses to immunotherapies and targeted therapies
• Measures critical biomarkers in B-cell malignancies
• Multiple sample types acceptable for testing
Whole blood
Bone marrow aspirate
2-5 mL plasma
4-10 mL blood
0.2-0.4 mL bone marrow aspirate
8 days
*CLIA-certified assay requires two tubes of 10 mL whole blood
PredicineHEME™ is a 259 gene assay that targets known mutations associated with B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). The assay can help guide decisions for immunotherapy, targeted therapy and relevant clinical trials for blood cancers. It is currently used in clinical research.
Available in RUO and CLIA-validated assay
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.
If you have any questions or need assistance, complete this form and we will respond within 24 hours.